Nitecapone (BioDeep_00000036556)

   

human metabolite Endogenous


代谢物信息卡片


3-[(3,4-dihydroxy-5-nitrophenyl)methylidene]pentane-2,4-dione

化学式: C12H11NO6 (265.0586346)
中文名称: 硝替卡朋
谱图信息: 最多检出来源 Bos taurus(endogenous) 50%

分子结构信息

SMILES: CC(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C(=O)C
InChI: InChI=1S/C12H11NO6/c1-6(14)9(7(2)15)3-8-4-10(13(18)19)12(17)11(16)5-8/h3-5,16-17H,1-2H3

描述信息

Nitecapone belongs to the family of Nitrophenols and Derivatives. These are compounds containing a nitrophenol moiety, which consists of a benzene ring bearing both an hydroxyl group and a nitro group on two different ring carbon atoms.
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
D004791 - Enzyme Inhibitors > D065098 - Catechol O-Methyltransferase Inhibitors
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents
D020011 - Protective Agents > D000975 - Antioxidants
C471 - Enzyme Inhibitor

同义名列表

3 个代谢物同义名

3-[(3,4-dihydroxy-5-nitrophenyl)methylidene]pentane-2,4-dione; 3-(3,4-Dihydroxy-5-nitrobenzylidine)-2,4-pentanedione; Nitecapone



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Shawn Stanley, Derek Deng, Koos Van den Berg, Hsiao Ching Foo. The equine metabolism of the catechol-O-methyltransferase enzyme inhibitor nitecapone. Drug testing and analysis. 2022 May; 14(5):929-935. doi: 10.1002/dta.3163. [PMID: 34545698]
  • Fernando R Ibarra, Inés Armando, Susana Nowicki, Andrea Carranza, Verónica De Luca Sarobe, Elvira E Arrizurieta, Marta Barontini. Dopamine is metabolised by different enzymes along the rat nephron. Pflugers Archiv : European journal of physiology. 2005 Jun; 450(3):185-91. doi: 10.1007/s00424-005-1386-6. [PMID: 15864503]
  • M A Vieira-Coelho, P Gomes, M P Serrão, P Soares-da-Silva. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors. Kidney international. 2001 May; 59(5):1683-94. doi: 10.1046/j.1523-1755.2001.0590051683.x. [PMID: 11318939]
  • L Nagy, R E Morales, M Beinborn, P Vattay, S Szabo. Investigation of gastroprotective compounds at subcellular level in isolated gastric mucosal cells. American journal of physiology. Gastrointestinal and liver physiology. 2000 Dec; 279(6):G1201-8. doi: 10.1152/ajpgi.2000.279.6.g1201. [PMID: 11093942]
  • T Vainikka, L Heikkilä, H J Toivonen, J Rämö, T A Hyytinen, S P Mattila. The effect of nitecapone on early graft function in experimental single lung transplantation. Scandinavian cardiovascular journal : SCJ. 2000 Aug; 34(4):415-20. doi: 10.1080/14017430050196261. [PMID: 10983677]
  • M A Lal, A Körner, Y Matsuo, S Zelenin, S X Cheng, G Jaremko, G F DiBona, A C Eklöf, A Aperia. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes. 2000 Aug; 49(8):1381-9. doi: 10.2337/diabetes.49.8.1381. [PMID: 10923641]
  • J Petäjä, E Pesonen, J A Fernández, A E Vento, O J Rämö, J H Griffin. Cardiopulmonary bypass and activation of antithrombotic plasma protein C. The Journal of thoracic and cardiovascular surgery. 1999 Sep; 118(3):422-9; discussion 429. doi: 10.1016/s0022-5223(99)70178-9. [PMID: 10469954]
  • A E Vento, J Aittomäki, K A Verkkala, L J Heikkilä, J A Salo, J Sipponen, O J Rämö. Nitecapone as an additive to crystalloid cardioplegia in patients who had coronary artery bypass grafting. The Annals of thoracic surgery. 1999 Aug; 68(2):413-20. doi: 10.1016/s0003-4975(99)00514-7. [PMID: 10475405]
  • A E Vento, O J Rämö, A T Nemlander, M Ahotupa, E Nissinen, A Holopainen, S P Mattila. Nitecapone inhibits myeloperoxidase in vitro and enhances functional performance after 8 h of ischemia in experimental heart transplantation. Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie. 1999 Apr; 198(6):299-306. doi: 10.1007/s004330050113. [PMID: 10369086]
  • G Léger, A Gjedde, H Kuwabara, M Guttman, P Cumming. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness. Synapse (New York, N.Y.). 1998 Dec; 30(4):351-61. doi: 10.1002/(sici)1098-2396(199812)30:4<351::aid-syn2>3.0.co;2-2. [PMID: 9826227]
  • H Brismar, M Asghar, R M Carey, P Greengard, A Aperia. Dopamine-induced recruitment of dopamine D1 receptors to the plasma membrane. Proceedings of the National Academy of Sciences of the United States of America. 1998 May; 95(10):5573-8. doi: 10.1073/pnas.95.10.5573. [PMID: 9576924]
  • M Scheinin, A Illi, M Koulu, P Ojala-Karlsson. Norepinephrine metabolites in plasma as indicators of pharmacological inhibition of monoamine oxidase and catechol O-methyltransferase. Advances in pharmacology (San Diego, Calif.). 1998; 42(?):367-70. doi: 10.1016/s1054-3589(08)60767-x. [PMID: 9327918]
  • J E Holden, D Doudet, C J Endres, G L Chan, K S Morrison, F J Vingerhoets, B J Snow, B D Pate, V Sossi, K R Buckley, T J Ruth. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1997 Oct; 38(10):1568-74. doi: NULL. [PMID: 9379194]
  • A C Eklöf, U Holtbäck, M Sundelöf, S Chen, A Aperia. Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na+,K+-ATPase. Kidney international. 1997 Sep; 52(3):742-7. doi: 10.1038/ki.1997.390. [PMID: 9291195]
  • A E Vento, O J Rämö, A T Nemlander, E Nissinen, A Holopainen, S P Mattila. Nitecapone is of benefit to functional performance in experimental heart transplantation. Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie. 1997; 197(3):137-46. doi: 10.1007/s004330050063. [PMID: 9406281]
  • M O Pentikäinen, K A Lindstedt, P T Kovanen. Inhibition of the oxidative modification of LDL by nitecapone. Arteriosclerosis, thrombosis, and vascular biology. 1995 Jun; 15(6):740-7. doi: 10.1161/01.atv.15.6.740. [PMID: 7773727]
  • E Nissinen, I B Lindén, P Pohto. Antioxidant properties of nitecapone are potentiated by glutathione. Biochemistry and molecular biology international. 1995 Feb; 35(2):387-95. doi: ". [PMID: 7663394]
  • K H Valkonen, T Wadström, A P Moran. Interaction of lipopolysaccharides of Helicobacter pylori with basement membrane protein laminin. Infection and immunity. 1994 Sep; 62(9):3640-8. doi: 10.1128/iai.62.9.3640-3648.1994. [PMID: 8063380]
  • S Kaakkola, A Gordin, P T Männistö. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. General pharmacology. 1994 Sep; 25(5):813-24. doi: 10.1016/0306-3623(94)90082-5. [PMID: 7835624]
  • T Wikberg, A Vuorela. Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile. European journal of drug metabolism and pharmacokinetics. 1994 Apr; 19(2):125-35. doi: 10.1007/bf03188833. [PMID: 8001593]
  • R S Miletich, G Comi, K Bankiewicz, R Plunkett, R Adams, G Di Chiro, I J Kopin. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Brain research. 1993 Oct; 626(1-2):1-13. doi: 10.1016/0006-8993(93)90556-3. [PMID: 8281420]
  • T Wikberg, J Taskinen. Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in the rat and dog. Drug metabolism and disposition: the biological fate of chemicals. 1993 Mar; 21(2):325-33. doi: NULL. [PMID: 8097704]
  • M Valenza, E Serbinova, L Packer, S Khwaja, J Catudioc. Nitecapone protects the Langendorff perfused heart against ischemia-reperfusion injury. Biochemistry and molecular biology international. 1993 Mar; 29(3):443-9. doi: ". [PMID: 8485462]
  • S Sundberg, M Scheinin, P Ojala-Karlsson, J Akkila, A Gordin. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition. European journal of clinical pharmacology. 1993; 44(3):287-90. doi: 10.1007/bf00271374. [PMID: 8491246]
  • Y J Suzuki, M Tsuchiya, A Safadi, V E Kagan, L Packer. Antioxidant properties of nitecapone (OR-462). Free radical biology & medicine. 1992 Nov; 13(5):517-25. doi: 10.1016/0891-5849(92)90146-8. [PMID: 1334029]
  • A Laihinen, J O Rinne, U K Rinne, M Haaparanta, U Ruotsalainen, J Bergman, O Solin. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology. 1992 Jan; 42(1):199-203. doi: 10.1212/wnl.42.1.199. [PMID: 1734304]
  • P Ottoila, E Pakkala, C Karlsson, J Taskinen. Determination of nitecapone and (13C6)nitecapone in human plasma by gas chromatography/mass spectrometry. Biological mass spectrometry. 1991 Dec; 20(12):771-6. doi: 10.1002/bms.1200201205. [PMID: 1812986]
  • J M Cedarbaum, G Leger, M Guttman. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clinical neuropharmacology. 1991 Aug; 14(4):330-42. doi: 10.1097/00002826-199108000-00005. [PMID: 1913700]
  • T Wikberg, J Taskinen. Determination of a catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by liquid chromatography. Journal of pharmaceutical and biomedical analysis. 1991; 9(1):59-64. doi: 10.1016/0731-7085(91)80238-5. [PMID: 2043724]
  • E Schultz, S Tarpila, A C Bäckström, A Gordin, E Nissinen, P Pohto. Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone. European journal of clinical pharmacology. 1991; 40(6):577-80. doi: 10.1007/bf00279973. [PMID: 1884738]
  • J Taskinen, T Wikberg, P Ottoila, L Kanner, T Lotta, A Pippuri, R Bäckström. Identification of major metabolites of the catechol-O-methyltransferase-inhibitor nitecapone in human urine. Drug metabolism and disposition: the biological fate of chemicals. 1991 Jan; 19(1):178-83. doi: NULL. [PMID: 1673395]
  • J M Cedarbaum, G Léger, A Reches, M Guttman. Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys. Clinical neuropharmacology. 1990 Dec; 13(6):544-52. doi: 10.1097/00002826-199012000-00006. [PMID: 2276119]
  • S Kaakkola, A Gordin, M Järvinen, T Wikberg, E Schultz, E Nissinen, P J Pentikäinen, H Rita. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clinical neuropharmacology. 1990 Oct; 13(5):436-47. doi: 10.1097/00002826-199010000-00005. [PMID: 2272023]
  • S Sundberg, M Scheinin, P Ojala-Karlsson, S Kaakkola, J Akkila, A Gordin. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone. Clinical pharmacology and therapeutics. 1990 Oct; 48(4):356-64. doi: 10.1038/clpt.1990.163. [PMID: 2225697]